Global Angiotensin Converting Enzymes (ACE) Inhibitors Market to Surpass US$ 12.4 Billion by 2026
SEATTLE, June 25, 2019 /PRNewswire/ -- According to Coherent Market Insights, the global angiotensin converting enzymes (ACE) inhibitors market was valued at US$ 11,693.6 million in 2017, and is projected to exhibit a CAGR of 0.8% during the forecast period (2018 – 2026).
Key Trends and Analysis of Angiotensin Converting Enzymes (ACE) Inhibitors Market:
Increasing launch of new products for the treatment of hypertension is expected to drive growth of the angiotensin converting enzyme (ACE) inhibitors market. For instance, in March 2018, Sandoz Canada announced the launch of new generic alternative therapies, Coversyl (containing Perindopril Arginine) and Coversyl Plus (containing Perindopril Arginine and Indapamide Hemihydrate) for treatment of hypertension.
Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2746
Moreover, in January 2017, Silvergate Pharmaceuticals, Inc. launched Epaned (containing Enalapril), an oral solution, for the treatment of hypertension, symptomatic heart failure, and asymptomatic left ventricular dysfunction in adults and children. Therefore, increasing launch of new products is expected to support growth of the ACE inhibitors market.
Increasing drug approval activities by the U.S. Food and Drug Administration (FDA) is also expected to boost the angiotensin converting enzymes (ACE) inhibitors market growth. For instance, in August 2016, Silvergate Pharmaceutical Inc. received the U.S. FDA approval for its Qbrelis, containing Lisinopril, an oral solution 1 mg/ml. This drug is indicated for the treatment of hypertension in adults and children.
Among regions, North America angiotensin converting enzymes (ACE) inhibitors market is expected to account for the largest market share over the forecast period, owing to increasing number of research and development activities in this region. For instance, in December 2016, Novartis Pharmaceuticals initiated clinical phase III study by using Ramipril, valsartan, placebo of Ramipril, and valsartan for the treatment of acute myocardial infraction. This study is expected to complete in July 2020.
To know the latest trends and insights prevalent in this market, click the link below:
Key Market Takeaways:
- The global angiotensin converting enzymes (ACE) inhibitors market is projected to witness a CAGR of 0.8% during the forecast period (2018 – 2026), owing to increasing prevalence of hypertension. For instance, according the World Health Organization's report, around 207 million people annually suffer from hypertension in India.
- Among regions, Asia Pacific is expected to witness significant growth in the angiotensin converting enzymes (ACE) inhibitors market, owing to increasing awareness activities of hypertension and its prevention this region. For instance, in May 2018, Indian Council of Medical research (ICMR) announced the launch of awareness campaign on hypertension in collaboration with Public Health Foundation of India.
- Major players operating in the global angiotensin converting enzymes (ACE) inhibitors market include, Pfizer, Inc., AstraZeneca Pharmaceutical Company, Novartis AG, Daiichi Sankyo Company, Ltd., United Therapeutics Corporation, Sanofi S.A., Johnson & Johnson Services, Inc., Merck KGaA, Takeda Pharmaceutical Company, and Bayer AG.
Buy this report now @ https://www.coherentmarketinsights.com/insight/buy-now/2746
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave.
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
SOURCE Coherent Market Insights
Share this article